Mortality in the Highly Active Antiretroviral Therapy Era
JAIDS Journal of Acquired Immune Deficiency SyndromesPublished 28 July 2006
Frank J. Palella, Rose Baker, Anne C. Moorman, Joan S. Chmiel, Kathleen C. Wood, John T. Brooks
Citations1,339
SJR quartileQ1
SJR score1.04
SNIP0.81
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Although overall death rates remained low through 2004, the proportion of deaths attributable to non- AIDS diseases increased and prominently included hepatic, cardiovascular, and pulmonary diseases, as well as non-AIDS malignancies.
Abstract
Although overall death rates remained low through 2004, the proportion of deaths attributable to non-AIDS diseases increased and prominently included hepatic, cardiovascular, and pulmonary diseases, as well as non-AIDS malignancies. Longer time spent receiving HAART and higher CD4 cell counts at HAART initiation were associated with death from non-AIDS causes. CD4 cell count at time of death increased over time.
Keywords
Medicine
New England Journal of MedicineDeclining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus Infection
9,465 Citations1998Frank J. Palella, Kathleen M. Delaney +6 more
The recent declines in morbidity and mortality due to AIDS are attributable to the use of more intensive antiretroviral therapies.
TechnometricsApplied Regression Analysis and Other Multivariable Methods
8,351 Citations1989Esteban Walker, David G. Kleinbaum +2 more
AIDSA syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
2,397 Citations1998Andrew Carr, Katherine Samaras +5 more
A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance is a common complication of HIV protease inhibitors and diabetes mellitus is relatively uncommon.
The LancetChanging patterns of mortality across Europe in patients infected with HIV-1
1,284 Citations1998Amanda Mocroft, Stefano Vella +9 more
Death rates across Europe among patients infected with HIV-1 have been falling since September, 1995, and at the beginning of 1998 were less than a fifth of their previous level.
The LancetDecline in the AIDS and death rates in the EuroSIDA study: an observational study
1,239 Citations2003Amanda Mocroft, Bruno Ledergerber +8 more
The initial drop in mortality and morbidity after the introduction of HAART has been sustained and potential long-term adverse effects associated with HAART have not altered its effectiveness in treating AIDS.
New England Journal of MedicinePeginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection in HIV-Infected Patients
1,230 Citations2004Francesca J. Torriani, M. Rodríguez‐Torres +14 more
Among patients infected with both HIV and HCV, the combination of peginterferon alfa-2a plus ribavirin was significantly more effective than either interferonalfa- 2a plus Ribavirin or pegin terferonAlfa-3a monotherapy.
New England Journal of MedicinePeginterferon Alfa-2a plus Ribavirin versus Interferon Alfa-2a plus Ribavirin for Chronic Hepatitis C in HIV-Coinfected Persons
873 Citations2004Raymond T. Chung, Janet Andersen +12 more
The marked discrepancy in the rates of sustained virologic response between HCV genotypes indicates that strategies are needed to improve the outcome in persons infected withHCV genotype 1.
The LancetProtease inhibitors and cardiovascular outcomes in patients with HIV-1
488 Citations2002Scott D. Holmberg, Anne C. Moorman +6 more
It is suggested that, although infrequent, use of protease inhibitors is associated with increased risk of myocardial infarction in patients with HIV-1.
AIDSNatural history of HIV infection in the_era of combination antiretroviral therapy
454 Citations1999Richard D. Moore, Richard E. Chaisson
A significant decline in the incidence of opportunistic illness and death from 1994 through 1998 associated with combination antiretroviral therapy was observed and the concurrent CD4 level was most strongly associated with developing an event.
Annals of Internal MedicineSurvival Benefit of Initiating Antiretroviral Therapy in HIV-Infected Persons in Different CD4+ Cell Strata
444 Citations2003Frank J. Palella, Maria Deloria Knoll +6 more
This cohort study compares mortality rates among ambulatory HIV-infected patients who initiated ART and those who delayed ART in various CD4+ strata and defines HAART as the use of at least three drugs simultaneously.
AIDSClinical assessment of HIV-associated lipodystrophy in an ambulatory population
426 Citations2001Kenneth A. Lichtenstein, Douglas Ward +7 more
JAIDS Journal of Acquired Immune Deficiency SyndromesManagement of Metabolic Complications Associated With Antiretroviral Therapy for HIV-1 Infection: Recommendations of an International AIDS Society–USA Panel
382 Citations2002Morris Schambelan, Constance A. Benson +10 more
International Journal of EpidemiologyCauses of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS
369 Citations2004Charlotte Lewden
Improved strategies for detecting HIV infection before AIDS-defining complications occur are needed in the era of HAART, and the prevention of non-AIDS related cancers, the management ofnon-Hodgkin's lymphoma, and of viral hepatitis are also important priorities.
Annals of Internal MedicineEffect of Medication Adherence on Survival of HIV-Infected Adults Who Start Highly Active Antiretroviral Therapy When the CD4+ Cell Count Is 0.200 to 0.350 × 10<sup>9</sup> cells/L
363 Citations2003Evan Wood, Robert S. Hogg +4 more
The effect of baseline CD4+ cell count and adherence on survival rates after the initiation of HAART was evaluated and it was suggested that delaying HAART after the CD4- cell count declines below 0.350 109 cells/L may be unsafe.
Clinical Infectious DiseasesLongitudinal Evolution of Bone Mineral Density and Bone Markers in Human Immunodeficiency Virus–Infected Individuals
304 Citations2003Kristin Mondy, Kevin E. Yarasheski +6 more
Traditional risk factors and advanced HIV infection play a more significant pathogenic role in the development of osteopenia and osteoporosis associated with HIV infection than do treatment-associated factors.
The Journal of Infectious DiseasesCombination Antiretroviral Therapy and Recent Declines in AIDS Incidence and Mortality
279 Citations1999Eric Vittinghoff, Susan Scheer +4 more
Declines in incidence of HIV infection, changes in HIV virulence, and end-point underreporting cannot fully explain the decline in AIDS and death in 1996, but the introduction of combination antiretroviral therapy as the standard of care may already have had measurable effects.
JAIDS Journal of Acquired Immune Deficiency SyndromesIncidence of and Risk Factors for Lipoatrophy (Abnormal Fat Loss) in Ambulatory HIV-1-Infected Patients
203 Citations2003Kenneth Lichtenstein, Kathleen M. Delaney +5 more
Some host factors and factors associated with previous or current severity of HIV infection, especially CD4 T-lymphocyte cell count, appeared to have the strongest association with incidence of lipoatrophy.
The Journal of Infectious DiseasesLiver Fibrosis Progression Is Related to CD4 Cell Depletion in Patients Coinfected with Hepatitis C Virus and Human Immunodeficiency Virus
197 Citations2001Massimo Puoti, Maurizio Bonacini +10 more
It is suggested that HIV infection-induced CD4 depletion is independently associated with the severity of liver fibrosis in chronic HCV infection.
The Journal of Infectious DiseasesTrends in Causes of Death among Persons with Acquired Immunodeficiency Syndrome in the Era of Highly Active Antiretroviral Therapy, San Francisco, 1994–1998
197 Citations2002Janice K. Louie, Ling Hsu +3 more
To understand recent temporal trends in acquired immunodeficiency syndrome (AIDS) mortality in the era of highly active antiretroviral therapy (HAART), trends in causes of death among persons with AIDS in San Francisco who died between 1994 and 1998 were analyzed.
AIDSEffectiveness of potent antiretroviral therapies on the incidence of opportunistic infections before and after AIDS diagnosis
187 Citations2001Roger Detels, Patrick M. Tarwater +4 more
The hazard of OI in the era of potent antiretroviral therapy has declined dramatically compared with the eraof monotherapy, despite the concurrent decrease in the use of prophylactic drugs.
AIDSDurability and predictors of success of highly active antiretroviral therapy for ambulatory HIV-infected patients
146 Citations2002Frank J. Palella, Joan S. Chmiel +2 more
Durable response to HAART was associated with being pre-HAART therapy naive, prompt response toHAART, and single protease inhibitor-based initial HAART (indinavir or nelfinavir).
AIDSVisiting Solomon: AIDS in Ethiopia
72 Citations2002Richard M. Hodes
The author narrates his experience as a physician in Ethiopia a nation with a per-capita Gross National Product of US$100 male life expectancy below 42 years and WHO Health System Attainment ranked 186 out of 191.
Annals of EpidemiologyChanging Conditions and Treatments in a Dynamic Cohort of Ambulatory HIV Patients
71 Citations1999Anne C. Moorman, Scott D. Holmberg +10 more
A nested analysis showed that HIV-infected cigarette smokers were at substantially greater risk of pneumonia than nonsmokers, and the HOPS provides continually updated information on the changing characteristics, conditions, and therapy of ambulatory HIV- infected patients.
Clinical Infectious DiseasesMechanisms and Strategies for Insulin Resistance in Acquired Immune Deficiency Syndrome
58 Citations2003Steven Grinspoon
Preliminary studies have suggested that metformin, an insulin sensitizing agent, improves insulin sensitivity, blood pressure, and waist circumference, and initial studies of thiazolidinediones also suggest the potential utility of such agents to improve insulinensitivity, decrease hepatic steatosis, and increase subcutaneous fat.
JAIDS Journal of Acquired Immune Deficiency SyndromesRecent Trends in HIV-Related Inpatient Admissions 1996–2000
51 Citations2003John A. Fleishman, Fred H. Hellinger
The trend in HIV-related inpatient hospital admissions is level in recent years, and racial/ethnic disparities in inpatient utilization persist.
Joint Bone SpineOsteopenia in patients infected by the human immunodeficiency virus. A case control study
49 Citations2002Sylvie Loiseau-Pérès, C. Delaunay +5 more
AIDSCauses of death in HIV infection
35 Citations2004Amanda Mocroft, José M. Gatell +7 more
Compared with homosexual individuals, IDU had an increased incidence of new AIDS/death, but only for non-HIV deaths, and there is an urgent need to define and standardize causes of death in observational studies.
Journal of HeredityMortality Rates and Causes of Death in a Cohort of HIV-Infected and Uninfected Women, 1993-1999
30 Citations2003Dawn K. Smith
The regression analysis findings, along with the high percentage of non-AIDS deaths attributable to illicit drug use, suggest that high levels of drug use in this population offset improvements in mortality from declining numbers of deaths due to AIDS.
AIDS Patient Care and STDsFactors Related to and Consequences of Adherence to Antiretroviral Therapy in an Ambulatory HIV-Infected Patient Cohort
22 Citations2004Maria Deloria Knoll, Joan S. Chmiel +5 more
Questions about difficulty taking antiretroviral medications or drug holidays identified an additional 16% of patients experiencing adherence problems and explained significantly more of the failure to achieve undetectable viral loads than simply querying about skipped doses.
AIDS Patient Care and STDsPrognostic Factors in Lactic Acidosis Syndrome Caused by Nucleoside Reverse Transcriptase Inhibitors: Report of Eight Cases and Review of the Literature
16 Citations2004Naga S. Tripuraneni, Peter R. Smith +3 more
Increased mortality with zidovudine in this study appears due in part to its greater use prior to 1990 when LAS was not widely recognized as a potential complication of NRTI therapy.